All articles tagged with #isomorphic labs
An anonymously sourced Semafor report says Demis Hassabis has been planning to step down as Google DeepMind CEO for about a year to become Alphabet’s chief scientist, while remaining DeepMind chair and heading Alphabet’s AI drug‑discovery arm Isomorphic Labs. Alphabet confirmed a broader leadership shakeup to sharpen its AI strategy, with Hassabis continuing to influence DeepMind’s and AlphaFold’s ecosystem.
Google is dismantling the Nobel-winning AlphaFold team, reassigning most researchers to Gemini-focused projects and Alphabet's Isomorphic Labs, with some members leaving for Anthropic, signaling a strategic shift to invest more resources in Gemini and related drug-discovery initiatives.
Google DeepMind has dismantled the AlphaFold team as it shifts strategy toward Gemini-powered AI to assist and automate scientific discovery, reassigning most AlphaFold researchers to projects in enzyme design, genomics, nuclear fusion and Isomorphic Labs; several core AlphaFold authors have left, including moves to Anthropic, reflecting a broader industry push to frontier AI systems beyond single science challenges.
Isomorphic Labs closed a $2.1 billion Series B, cementing its leadership in AI-driven drug discovery and prompting questions about how the funds will be deployed, pipeline progress, and the broader implications for biotech and AI investment.
Google DeepMind's affiliate, Isomorphic Labs, is preparing to begin human trials of AI-designed drugs, aiming to revolutionize drug development by increasing success rates and reducing costs, leveraging breakthroughs like AlphaFold for protein modeling.
Alphabet's Isomorphic Labs unit has announced research collaborations with Eli Lilly and Novartis to focus on small-molecule treatments and multiple targets using artificial intelligence for drug discovery, receiving upfront cash and possible milestone payments from both companies. Eli Lilly and Isomorphic Labs will collaborate on small molecule therapeutics for multiple targets, while the Novartis-Isomorphic collaboration will focus on finding small molecule therapeutics vs. three targets. Stocks for Eli Lilly and Novartis saw increases, while Alphabet's stock experienced a decline.
Isomorphic Labs, a drug discovery spin-out of DeepMind, has partnered with Eli Lilly and Novartis to use AI for drug discovery, with deals totaling $3 billion. Isomorphic will receive upfront payments and potential milestone-based incentives. The company utilizes DeepMind's AlphaFold 2 AI technology to predict protein structures, aiding in drug design. While not perfect, AlphaFold has shown promise in designing potential drugs for diseases like liver cancer and is being applied to neglected diseases. Isomorphic is under pressure to turn a profit after recording a loss in 2021.